Cellular Biology |
From the Laboratorio de Nefrología (M.A.C., M.V.A.A., F.R.G.-P., C.C.) and Servicio de Inmunología (E.A., E.T., R.B.), Fundación Jiménez Díaz, Servicio de Anatomía Patológica (P.A.), Hospital Clínico de San Carlos, Autónoma and Complutense Universities, Madrid, Spain.
Correspondence to C. Caramelo, MD, Fundación Jiménez Díaz, Universidad Autónoma, Av Reyes Católicos 2, 28040, Madrid, Spain.
| Abstract |
|---|
|
|
|---|
Key Words: vascular endothelial growth factor vascular endothelial cadherin endothelial cell cytoprotection proliferation
| Introduction |
|---|
|
|
|---|
Endothelial integrity implies the existence of
cell-to-cell interactions, which involve different types of junctions
between endothelial cells.5 Among them,
adherens junctions, which are constituted by a rather complex system,
including the endothelial cellspecific vascular
endothelial (VE) cadherin, catenins, plakoglobin, and
-actin, are instrumental for the integrity of the monolayer
structure.5 Cadherins are a multiple-gene family of
Ca2+-dependent cell adhesion molecules with a
typical single-spanning transmembrane structure and with homophilic
binding specificity. Cadherins localize at adherens junctions and
mediate physiological interactions involving
cytoplasmic anchoring molecules, catenins, and the actin-based
cytoskeleton network.5 6 7 8 The signaling system by which
these junctions participate in sensing the integrity of the
endothelial layer are, however, insufficiently
characterized. In research done in the early 1980s, Selden et
al2 described how agents that disrupt microtubule
structures of the cytoskeleton can trigger endothelial
cell proliferation. However, no specific mechanisms of this effect were
identified at that time, and these remain undefined.
The phenomenon of contact inhibition implies the absence of effect of growth factors participating in endothelial cell proliferation. The main sources for endothelial growth factors are paracrine. A relevant example of this is the production of vascular endothelial growth factor (VEGF) by vascular smooth muscle cells submitted to either in vivo or in vitro injuring conditions.9 10 11 12 VEGF is an endothelial cellspecific mitogen, which appears to be a crucial mediator of angiogenesis in different conditions.13 However, despite the role of paracrine VEGF, the development of capillary networks may require the existence of autocrine growth stimulation. In this regard, there is solid evidence supporting the existence of autocrine production of VEGF by endothelial cells in several conditions, of which hypoxia is the most representative.14 15 16 17 18 Nevertheless, no data are available to ascertain whether autocrine VEGF expression may be triggered in other situations, specially when the endothelial cell monolayer is injured and disrupted. Injured endothelia, either in vivo or in vitro, tend to reorganize and cover the denuded surfaces, therefore indicating that a repair program is activated by the injury. Accordingly, we hypothesized that the interruption of endothelial cell monolayer continuity will trigger both endothelial cell proliferation and autocrine production of growth factors. Based on this hypothesis, the aim of the present study was to assess the proliferative response and the autocrine VEGF expression on endothelial cells, under conditions of interruption of cell-to-cell adhesion. The main attention was focused on the production of VEGF.
| Materials and Methods |
|---|
|
|
|---|
Electron Microscopy (EM)
Confluent BAECs were treated as described.22
DNA Synthesis Assay
Uptake of [3H]thymidine was measured as
described.19
Analysis of the mRNA Expression of VEGF
Total RNA was isolated from confluent monolayers 3 hours after
the different treatments (see below). Reverse transcriptasepolymerase
chain reaction (PCR) and Northern blot were performed as
described.20 Oligonucleotide primers of
human VEGF were synthesized according to established
sequences.23 The PCR products were analyzed by
automatic sequencing (373 DNA sequencer, Applied Biosystems). GAPDH was
used as a control gene.
Immunocytochemistry of VEGF Expression
Confluent and subconfluent BAECs grown on glass chamber slides
(Nalge Nunc) were submitted to the different experimental maneuvers,
washed with PBS, and incubated in MEM D-valine
without FCS for an additional 24 hours and then fixed in 95% ethanol.
Immunostaining was performed by a modification of
described methods, using a specific anti-VEGF antibody raised in our
institution.24
Western Blot Analysis of VEGF
Confluent BAECs were submitted to the different experimental
maneuvers, washed with PBS, and incubated in MEM D-valine
without FCS for an additional 24 hours. Then, cells were extracted with
0.5% (octylphenoxy)polyethoxyethanol (Igepal CA-630; Sigma) in
Tris-buffered saline containing protease inhibitors.
Samples separated by SDS-PAGE and transferred onto nitrocellulose
(Bio-Rad Laboratories) were probed with anti-VEGF monoclonal antibody
(mAb; 1/250; Sigma) and reprobed with a mouse monoclonal
anti
-tubulin to normalize to equivalent gel loading.
Flow Cytometry
These experiments were done as described,25 using
an EPICS-XL MCL cytometer (Coulter) and the Mcycle program (Coulter)
for evaluating cell death.
Assay of Cytotoxicity and Measurement of Cytosolic Ca2+
Concentration ([Ca2+]i) by Fura-2
Cytotoxicity and
[Ca2+]i were measured as
described, by 51Cr release and fura-2,
respectively.20 26
Experimental Maneuvers
Intercellular adhesion of BAECs was disrupted by treatment with
EGTA (2 mmol/L, 30 minutes), cytochalasin D (CytD; 0.2 µg/mL, 60
minutes; Sigma) or VE-cadherin mAb (VE-mAb; 0.25 µg/mL, 60 minutes;
Transduction Laboratories), as described.27 28 29 30 Monoclonal
anti-PTHrP (0.25 µg/mL) and nonspecific rabbit IgG (0.25 µg/mL)
were used as controls without effects on VE-cadherin. BAECs were also
exposed to antibodies against CD31 (0.25 µg/mL) and CD34 (0.25
µg/mL) antigens, which are highly expressed in
endothelial cells but are not involved in VE-cadherin
junctions and do not produce a significant
[Ca2+]i signal (M.A.
Castilla et al, unpublished results, 1998). When indicated, a
specific anti-VEGF mAb (0.5 mg/mL, 1:500; Sigma) was used to block VEGF
effects.20 To assess the triggering of VEGF expression by
other means, a mechanical endothelial wound was done by
using a sterile 200-µL pipette tip.
Statistics
Results are expressed as mean±SEM. Unless otherwise stated,
each value corresponds to a minimum of 5 triplicate experiments.
Comparisons were done by 1-way ANOVA and Scheffé test, Kruskal
Wallis and Dunn tests, and paired and unpaired Student t and
Bonferroni tests when appropriate. P was considered
significant at
0.05.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
|
Effects of Disruption of Intercellular Adhesion on VEGF mRNA
Expression and VEGF Production
A moderate, albeit consistent basal expression of VEGF
mRNA corresponding to 3 isoforms was present in BAECs (Figure 2
); this expression appeared to be
enhanced, particularly for the 165amino acid isoform, with the 3
maneuvers disrupting BAEC intercellular adhesion. For more accurate
quantification, Northern blot experiments were performed. These
experiments revealed an increased VEGF mRNA expression in BAECs treated
with the disruption maneuvers. An image of a
representative Northern blot is depicted in Figure 3
(top). Quantification of VEGF mRNA
expression against 28S cDNA (Figure 3
, bottom) demonstrated a
significant increment with respect to the control, with all 3
maneuvers. Separate experiments revealed that the
simultaneous treatments with EGTA and VE-mAb were
nonadditive (P=NS between the expression of VEGF mRNA in
BAECs treated with either 2 mmol/L EGTA or 0.25 µg/mL
VE-mAb alone versus 2 mmol/L EGTA+0.25 µg/mL VE-mAb). No effect
on VEGF expression was detected with the nonVEGF-specific antibodies;
these antibodies did not provoke changes in
[Ca2+]i (data not shown),
therefore suggesting the absence of intracellular signaling produced by
the antibody itself.
|
|
A similar stimulating effect was obtained when VEGF protein
production was assessed by Western blotting. As shown in Figure 4
, lanes 4 through 6, an increased VEGF
band intensity was detected with EGTA, CytD, and VE-mAb. In
quantitative data corresponding to the mean of 3 experiments showing
similar results, we have found the following values of VEGF protein
increment with respect to the baseline: EGTA, 5.3±0.6 times
(P<0.01); CytD, 4.2±0.5 times (P<0.01),
VE-mAb, 16.2±0.6 times (P<0.001), anti-CD31, 1.4±0.3
times (P=NS); and anti-CD34, 1±0.2 times
(P=NS). In the same line of evidence, an increased
VEGF immunostaining was detected in the areas
surrounding an endothelial wound (Figure 5A
). Furthermore, to assess whether the
increased expression of VEGF was due to the disruption or to the lack
of formation of the intercellular junctions, BAECs were examined by
immunocytochemistry at the subconfluent state. Of interest, a marked
VEGF immunostaining was evident in subconfluent BAECs
(Figure 5B
). The latter experiments were the only performed in
nonconfluent cells. Although these results are not shown, because they
provide a similar kind of information as the Western blot results
showing an increase in VEGF protein, the exposure of BAECs to EGTA,
CytD, and VE-mAb (similar concentrations as above) increased VEGF
immunocytochemical staining in a diffuse pattern on the entire
preparation.
|
|
Functional Implications of the Stimulation of VEGF
Production by Loss of the Adherens Junctions
A major effect of the 3 treatments was observed on cell protection
against FBS deprivation. This effect was assessed by flow
cytometry (Figure 6A
through 6C
). As can
be seen, the 3 treatments afforded a relevant degree of protection
against cell death within a range close to that obtained by incubation
with 20% FBS. This cytoprotective effect was completely inhibited in
the presence of anti-VEGF mAb (Figure 6A
through 6C
). No effects
of the anti-VEGF mAb by itself were observed (percentage of cell death,
37.6±1.9, P=NS with respect to baseline; untreated cells,
n=4). Of interest, the simultaneous incubation of BAECs
with CytD and anti-VEGF mAb did actually produce an increment in cell
death with respect to the baseline (Figure 6B
). Finally, the
treatment with 2 of the 3 maneuvers, namely CytD and VE-mAb, increased
endothelial cell DNA synthesis, as assessed by
[3H]thymidine uptake and cell number (Figure 7A
and 7B
). As can be observed, EGTA
incubation differed from the other 2 maneuvers in that it did not
increase DNA synthesis in the same proportion. In any case, the
magnitude of the increase in [3H]thymidine with
CytD and VE-mAb was substantially smaller when compared with the
stimulation reached with 20% FBS (70.6±4 times increase in
[3H]thymidine uptake,
P<0.0001 between 20% FBS versus CytD and VE-mAb).
|
|
| Discussion |
|---|
|
|
|---|
Reports from other investigators provided the theoretical background for the present study. Previously published data have related the disruption of microtubule structures with cell proliferation.2 More recently, Ingber et al31 ascertained the importance of actin-containing microfilaments in shape-dependent growth control by culture cells in the presence of CytD that, in short-term incubations, produced mitogenic effects. Our results not only confirm the reports of Ingber et al31 in terms of the growth-promoting effect of brief exposures to CytD, but also provide an explanation, based on the effects of the stimulated VEGF production, for the previously unexplained induction of endothelial cell proliferation by CytD. In addition, the present results demonstrate that the effects of CytD to promote endothelial cell gene expression, which were already described for the endothelin 1 gene,29 involve also VEGF expression. In a second set of previous data related to our findings, recent studies demonstrated that cell proliferation becomes inhibited after transfecting cadherin-lacking cells with VE-cadherin.32 Our results using the VE-mAb, therefore, mirror the aforementioned effects of VE-cadherin transfection. Functionally, the present experiments demonstrate that the attack of the VE-cadherin junctions with the VE-mAb triggers cytoprotection and DNA synthesis on endothelial cells. Giving further pathophysiological significance to this finding, an increased VEGF expression and vessel growth has been observed in blistering skin diseases, which are causally related to autoantibodies directed to members of the cadherin gene superfamily.6 33 34 Taken together, this information suggests that a relationship exists between cadherin system integrity, VEGF expression, and endothelial cell growth. The association found in pemphigus of immune disruption of intercellular adhesion and VEGF expression is coincident with our present in vitro findings, albeit in cells other than endothelial.
In mechanistic terms, the fact that in the present experiments the disruption at the level of either the extracellular or the intracellular domain of the adherens system, as obtained by means of the VE-mAb or EGTA or by means of CytD, respectively, triggered similar responses in BAECs suggests that both parts of the system are relevant to the regulation of growth and VEGF expression. Furthermore, the absence of additive effects between the different maneuvers in terms of VEGF expression, [3H]thymidine incorporation, or flow cytometry further suggest that similar pathways are involved. The differences found in the effect of EGTA exposure on [3H]thymidine incorporation and cell count indicate that the effect of EGTA in these circumstances occurred predominantly through cell protection without stimulating DNA synthesis. This is not surprising, taking into account the role of EGTA as a mitogenic inhibitor.35 36 However, the effects of the 3 maneuvers on [3H]thymidine incorporation were of small magnitude compared with the effect of 20% FBS. Taken together, these data suggest that the effects observed were more based on the promotion of cell survival rather than on stimulation of DNA synthesis; the latter probably was just a marginal, albeit statistically significant, phenomenon. In addition, the present data provide a sound basis for the importance of autocrine VEGF production as a survival mechanism under conditions of loss of integrity of the endothelial cell layer. A recent communication by Gerber et al37 has given support to the existence of an antiapoptotic role of VEGF on endothelial cells involving bcl-2 expression. Of special interest, the appearance of an augmented cell death in BAECs exposed to CytD in the presence of the VEGF-specific antibody uncovers the existence of CytD-related toxic effects on BAECs even after short exposures and strongly emphasizes the importance of VEGF as a cytoprotective mediator.
Our finding that endothelial cells have a small, but significant, basal VEGF mRNA expression are in agreement with reports from other groups using cultured endothelial cells of diverse origins.14 16 There is solid evidence demonstrating that VEGF production by endothelial cells is markedly stimulated in hypoxia and other hypoxia-like stimuli.38 These results indicate that autocrine and paracrine VEGFs may take part in the proliferation and death resistance of endothelial cells.15
In summary, our results provide further insight in the mechanisms by which endothelial cells react to the absence of their normal cell-to-cell anchorage. The consequences of this phenomenon may be of considerable magnitude under in vivo conditions, and the present findings may be useful to our understanding of the pathways initiating endothelial growth in several situations of vascular injury, as well as in neoangiogenesis. The triggering of autocrine VEGF expression on the disruption of interendothelial junctions may help explain the proliferative behavior of endothelial cells under conditions of loss of continuity of the monolayer, as occurs, eg, in angioplastic procedures.
| Acknowledgments |
|---|
Received June 30, 1999; accepted September 20, 1999.
| References |
|---|
|
|
|---|
2. Selden SC, Rabinovitch PS, Schwartz SM. Effects of cytoskeletal disrupting agents on replication of bovine endothelium. J Cell Physiol. 1981;108:195211.[Medline] [Order article via Infotrieve]
3.
Schwartz SM, Benditt EP. Aortic
endothelial cell replication. Circ Res. 1977;41:248255.
4. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. FASEB J. 1995;9:910918.[Abstract]
5. Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest. 1996;98:19491953.[Medline] [Order article via Infotrieve]
6. Amagai M. Adhesion molecules, I: keratinocyte-keratinocyte interactions; cadherins and pemphigus. J Invest Dermatol. 1995;104:146152.[Medline] [Order article via Infotrieve]
7.
Lampugnani MG, Corada M, Caveda L, Breviario F, Ayalon
O, Geiger B, Dejana E. The molecular organization of
endothelial cell to cell junctions: differential
association of plakoglobin, ß-catenin, and
-catenin with
vascular endothelial cadherin (VE-cadherin).
J Cell Biol. 1995;129:203217.
8.
Breviario F, Caveda L, Martin-Padura I, Navarro P,
Golay J, Introna M, Gulino D, Lampugnani MG, Dejana E. Functional
properties of human vascular endothelial cadherin
(7B4/cadherin-5), an endothelium-specific cadherin.
Arterioscler Thromb Vasc Biol. 1995;15:12291239.
9. Ferrara N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors. 1991;5:141148.[Medline] [Order article via Infotrieve]
10.
Van Belle E, Witzenbichler B, Chen D, Silver M, Chang
L, Schwall R, Isner JM. Potentiated angiogenic effect of scatter
factor/hepatocyte growth factor via induction of vascular
endothelial growth factor: the case for paracrine
amplification of angiogenesis. Circulation. 1998;97:381390.
11. González-Pacheco FR, Alvarez Arroyo MV, Castilla MA, Arias J, Bragado R, Caramelo C. Reactive oxygen species stimulate endothelial growth factor expression on vascular smooth muscle cells. J Am Soc Nephrol. 1997;8:587A. Abstract.
12.
Ruef J, Hu ZH, Yin LY, Wu Y, Hanson SR, Kelly BA,
Harker LA, Rao GN, Runge MS, Patterson C. Induction of vascular
endothelial growth factor in balloon-injured baboon
arteries: a novel role for reactive oxygen species in
atherosclerosis. Circ Res. 1997;81:2433.
13. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 1996;5:3544.[Medline] [Order article via Infotrieve]
14.
Uchida K, Uchida S, Nitta K, Yumura W, Marumo F, Nihei
H. Glomerular endothelial cells in culture
express and secrete vascular endothelial growth factor.
Am J Physiol. 1994;266:F81F88.
15.
Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal
T, Varticovski L, Isner JM. Hypoxia induces vascular
endothelial growth factor in cultured human
endothelial cells. J Biol Chem. 1995;270:3118931195.
16.
Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima
T, Yamashita J, Yamamoto H. Possible participation of autocrine and
paracrine vascular endothelial growth factors in
hypoxia-induced proliferation of endothelial
cells and pericytes. J Biol Chem. 1995;270:2831628324.
17. Fischer S, Sharma HS, Karliczek GF, Schaper W. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Brain Res Mol. 1995;28:141148.[Medline] [Order article via Infotrieve]
18.
Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia
regulates vascular endothelial growth factor gene
expression in endothelial cells: identification of a 5'
enhancer. Circ Res. 1995;77:638643.
19. Montón M, Castilla MA, Alvarez Arroyo MV, Tan D, González-Pacheco FR, López Farré A, Casado S, Caramelo C. Effects of angiotensin II on endothelial cell growth: role of AT-1 and AT-2 receptors. J Am Soc Nephrol. 1998;9:969974.[Abstract]
20. Alvarez Arroyo MV, Castilla MA, González-Pacheco FR, Tan D, Riesco A, Casado S, Caramelo C. Role of vascular endothelial growth factor on erythropoietin-related endothelial cells proliferation. J Am Soc Nephrol. 1998;11:19982004.
21.
López Farré A, Riesco A, Espinosa G,
Digiuni E, Cernadas MR, Alvarez V, Montón M, Rivas F, Gallego MJ,
Egido J, Casado S, Caramelo C. Effect of endothelin-1 on neutrophil
adhesion to endothelial cells and perfused heart.
Circulation. 1993;88:11661171.
22.
Tan D, Cernadas MR, Aragoncillo P, Castilla MA, Alvarez
Arroyo MV, López Farré AJ, Casado S, Caramelo C. Role of
nitric oxide-related mechanisms in renal function in ageing rats.
Nephrol Dial Transplant. 1998;13:594601.
23.
Tischer E, Mitchell R, Hartmarn T, Silva M,
Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular
endothelial growth factor. J Biol Chem. 1991;266:1194711954.
24. Bragado R, Bello E, Requena L, Renedo G, Texeiro E, Alvarez MV, Castilla MA, Caramelo C. Increased expression of vascular endothelial growth factor in pyogenic granulomas. Acta Dermatol Venereol. In press.
25. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271279.[Medline] [Order article via Infotrieve]
26. Okada K, Caramelo C, Tsai P, Schrier RW. Effect of inhibition of Na+/K+-adenosine triphosphatase on vascular action of arginine-vasopressin. J Clin Invest. 1990;86:12411248.
27.
Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L,
Lampugnani MG, Dejana E. Polymorphonuclear leukocyte adhesion
triggers the disorganization of endothelial
cell-to-cell adherens junctions. J Cell Biol. 1996;135:497510.
28. Gotsch U, Borges E, Bosse R, Böggemeyer E, Simon M, Mossmann H, Vestweber D. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J Cell Sci. 1997;110:583588.[Abstract]
29. Caveda L, Corada M, Martín Padura I, Del Maschio A, Breviario F, Lampugnani MG, Dejana E. Structural characteristics and functional role of endothelial cell to cell junctions. Endothelium. 1994;2:110.
30.
Morita T, Kurihara H, Maemura K, Yoshizumi M, Nagai R,
Yazaki Y. Role of Ca2+ and protein kinase C in
shear stress-induced actin depolymerization and
endothelin 1 gene expression. Circ Res. 1994;75:630636.
31. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech. 1995;28:14711484.[Medline] [Order article via Infotrieve]
32. Caveda L, Martín-Padura I, Navarro P, Breviario F, Corada M, Gulino D, Lampugnani MG, Dejana E. Inhibition of cell growth by vascular endothelial cadherin. J Clin Invest. 1996;98:886893.[Medline] [Order article via Infotrieve]
33.
Silos SA, Tamai K, Li K, Kivirikko S, Kouba D,
Christiano AM, Uitto J. Cloning of the gene for human pemphigus
vulgaris antigen (desmoglein 3), a desmosomal cadherin:
characterization of the promoter region and identification of a
keratinocyte-specific cis-element.
J Biol Chem. 1996;271:1750417511.
34. Brown LF, Harrist TJ, Yeo KT, Stahle-Backdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol. 1995;104:744749.[Medline] [Order article via Infotrieve]
35. Gelfand EW, Cheung RK, Mills GB, Grinstein S. Uptake of extracellular Ca2+ and not recruitment from internal stores is essential for T lymphocyte and proliferation. Eur J Inmunol. 1988;18:917922.
36. Tamagaki T, Sawada S, Imamura H, Tada Y, Yamasaki S, Toratani A, Sato T, Komatsu S, Akamatsu N, Yamagami M, Kobayashi K, Kato K, Yamamoto K, Shirai K, Yamada K, Higaki T, Nakagawa K, Tsuji H, Nakagawa M. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis. 1996;123:7382.[Medline] [Order article via Infotrieve]
37.
Gerber HP, Dixit V, Ferrara N. Vascular
endothelial growth factor induces expression of the
antiapoptotic proteins Bcl-2 and A1 in vascular
endothelial cells. J Biol Chem. 1998;273:1331313316.
38. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1998;1401:187194.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. J. P. Deudero, C. Caramelo, M. C. Castellanos, F. Neria, R. Fernandez-Sanchez, O. Calabia, S. Penate, and F. R. Gonzalez-Pacheco Induction of Hypoxia-inducible Factor 1{alpha} Gene Expression by Vascular Endothelial Growth Factor J. Biol. Chem., April 25, 2008; 283(17): 11435 - 11444. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Neria, C. Caramelo, H. Peinado, F. R. Gonzalez-Pacheco, J. JP. Deudero, A. J. de Solis, R. Fernandez-Sanchez, S. Penate, A. Cano, and M{a} A. Castilla Mechanisms of endothelial cell protection by blockade of the JAK2 pathway Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1123 - C1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Gonzalez-Pacheco, J. J. P. Deudero, M. C. Castellanos, M. A. Castilla, M. V. Alvarez-Arroyo, S. Yague, and C. Caramelo Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1395 - H1401. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-F. Wang, J. Z. Cui, S. S. Prasad, and J. A. Matsubara Altered Gene Expression of Angiogenic Factors Induced by Calcium-Mediated Dissociation of Retinal Pigment Epithelial Cells Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1508 - 1515. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ivanov, M. Philippova, R. Allenspach, P. Erne, and T. Resink T-cadherin upregulation correlates with cell-cycle progression and promotes proliferation of vascular cells Cardiovasc Res, October 1, 2004; 64(1): 132 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Castilla, F. Neria, G. Renedo, D. S. Pereira, F. R. Gonzalez-Pacheco, S. Jimenez, P. Tramon, J. J. P. Deudero, M. V. A. Arroyo, S. Yague, et al. Tumor-induced endothelial cell activation: role of vascular endothelial growth factor Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1170 - C1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Nelson and C. S. Chen VE-cadherin simultaneously stimulates and inhibits cell proliferation by altering cytoskeletal structure and tension J. Cell Sci., September 1, 2003; 116(17): 3571 - 3581. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. RODRIGUES, E. VAN AKEN, S. VAN BOCXLAER, S. ATTOUB, Q.-D. NGUYEN, E. BRUYNEEL, B. R. WESTLEY, F. E. B. MAY, L. THIM, M. MAREEL, et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling FASEB J, January 1, 2003; 17(1): 7 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Samarakoon and P. J. Higgins MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type 1 gene expression upon drug-induced disruption of the microfilament and microtubule networks J. Cell Sci., January 8, 2002; 115(15): 3093 - 3103. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Behzadian, X.-L. Wang, L. J. Windsor, N. Ghaly, and R. B. Caldwell TGF-{beta} Increases Retinal Endothelial Cell Permeability by Increasing MMP-9: Possible Role of Glial Cells in Endothelial Barrier Function Invest. Ophthalmol. Vis. Sci., March 1, 2001; 42(3): 853 - 859. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |